|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Candel Therapeutics, Inc. (CADL) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
28,690,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Candel Therapeutics is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Co. has oncolytic viral immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus constructs. Co.'s product candidate, CAN-2409, is an off-the-shelf adenovirus product candidate combined with the prodrug valacyclovir. Co. is conducting, as part of its CAN-2409 program, a clinical trial in the U.S. for CAN-2409 in patients with newly diagnosed localized prostate cancer who have an intermediate- or high-risk for progression. Co. is also developing its HSV platform product candidates for solid tumor indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
128,181 |
| Total Buy Value |
$0 |
$0 |
$0 |
$242,351 |
| Total People Bought |
0 |
0 |
0 |
6 |
| Total Buy Transactions |
0 |
0 |
0 |
13 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nichols Garrett |
Chief Medical Officer |
• – – |
2022-11-28 |
4 |
A |
$0.00 |
$0 |
D/D |
58,479 |
58,479 |
|
- |
|
| Barone Francesca |
Chief Scientific Officer |
• – – |
2022-11-28 |
4 |
A |
$0.00 |
$0 |
D/D |
90,877 |
92,377 |
|
- |
|
| Amello Jason |
Chief Financial Officer |
• – – |
2022-11-28 |
4 |
A |
$0.00 |
$0 |
D/D |
90,877 |
90,877 |
|
- |
|
| Tyagarajan Seshu |
See Remarks |
• – – |
2022-11-28 |
4 |
A |
$0.00 |
$0 |
D/D |
73,684 |
73,684 |
|
- |
|
| Aguilar-Cordova Estuardo |
Director |
– • • |
2022-05-06 |
4 |
D |
$3.65 |
$197,370 |
D/D |
(54,074) |
1,097,032 |
|
- |
|
| Aguilar-Cordova Estuardo |
Director |
– • • |
2022-05-06 |
4 |
OE |
$1.46 |
$197,367 |
D/D |
135,183 |
1,151,106 |
|
- |
|
| Aguilar Laura K. |
10% Owner |
– – • |
2022-05-06 |
4 |
D |
$3.65 |
$250,149 |
D/D |
(68,534) |
1,033,840 |
|
- |
|
| Aguilar Laura K. |
10% Owner |
– – • |
2022-05-06 |
4 |
OE |
$1.46 |
$250,149 |
D/D |
171,335 |
1,102,374 |
|
- |
|
| Barone Francesca |
Chief Scientific OfficerOffice |
• – – |
2022-02-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,500 |
|
- |
|
| Manning Paul B |
Director |
– • • |
2021-07-29 |
4/A |
B |
$8.00 |
$13,000,000 |
D/D |
1,625,000 |
1,681,000 |
3.92 |
- |
|
| Nguyen Diem |
Director |
– • – |
2021-07-29 |
4 |
B |
$8.00 |
$80,000 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Aguilar Laura K. |
Chief Medical Officer |
• – – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
56,096 |
931,039 |
|
- |
|
| Tak Paul Peter |
Chief Executive Officer |
• • – |
2021-07-29 |
4 |
B |
$8.00 |
$200,000 |
D/D |
25,000 |
25,000 |
2.81 |
- |
|
| Aguilar-Cordova Estuardo |
Chief Scientific Officer |
• • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
162,137 |
1,015,923 |
|
- |
|
| Manning Paul B |
Director |
– • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
I/I |
1,232,910 |
553,752 |
|
- |
|
| Martell Christopher |
Director |
– • – |
2021-07-29 |
4 |
B |
$8.00 |
$1,000,000 |
I/I |
125,000 |
125,000 |
2.1 |
- |
|
| Martell Christopher |
Director |
– • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
I/I |
283,514 |
283,514 |
|
- |
|
| Canepa John J |
Chief Financial Officer |
• – – |
2021-07-29 |
4 |
B |
$8.00 |
$81,000 |
D/D |
10,125 |
10,125 |
2.74 |
- |
|
| Caffo Nathan |
Chief Business Officer |
• – – |
2021-07-29 |
4 |
B |
$8.00 |
$48,000 |
D/D |
6,000 |
6,000 |
2.74 |
- |
|
| Manning Paul B |
Director |
– • – |
2021-07-29 |
4 |
B |
$7.30 |
$145,944 |
D/D |
20,000 |
56,000 |
2.39 |
- |
|
| Manning Paul B |
Director |
– • – |
2021-07-27 |
4 |
B |
$7.36 |
$264,834 |
D/D |
36,000 |
36,000 |
2.39 |
- |
|
46 Records found
|
|
Page 2 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
